Operates TRxADE HEALTH, an online web-based platform for pharmaceutical transactions. Connects licensed pharmaceutical wholesalers with various buying entities. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 54% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 32.8× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 13% of them.
No analyst target is on record for this company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $432K a year; the problem isn’t sales — it’s costs running above that number.
A loss of $41.5M against $432K in annual sales.
The stock sits at $0.35. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 4 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, SCNX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SCNX’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
Not covered, because the filings we hold do not carry it: the revenue breakdown.